nodes	percent_of_prediction	percent_of_DWPC	metapath
Flutamide—CYP1B1—ovarian cancer	0.484	1	CbGaD
Flutamide—CYP1B1—Paclitaxel—ovarian cancer	0.0905	0.303	CbGbCtD
Flutamide—CYP1B1—Docetaxel—ovarian cancer	0.0654	0.219	CbGbCtD
Flutamide—CYP1B1—Doxorubicin—ovarian cancer	0.0488	0.163	CbGbCtD
Flutamide—CYP3A5—Paclitaxel—ovarian cancer	0.0238	0.0798	CbGbCtD
Flutamide—CYP3A4—Topotecan—ovarian cancer	0.0188	0.0628	CbGbCtD
Flutamide—CYP3A5—Docetaxel—ovarian cancer	0.0172	0.0577	CbGbCtD
Flutamide—CYP3A4—Vinorelbine—ovarian cancer	0.0132	0.0443	CbGbCtD
Flutamide—CYP3A4—Paclitaxel—ovarian cancer	0.0093	0.0311	CbGbCtD
Flutamide—CYP3A4—Docetaxel—ovarian cancer	0.00672	0.0225	CbGbCtD
Flutamide—CYP3A4—Doxorubicin—ovarian cancer	0.00501	0.0168	CbGbCtD
Flutamide—AR—oviduct—ovarian cancer	0.00323	0.0911	CbGeAlD
Flutamide—AHR—myometrium—ovarian cancer	0.0021	0.0591	CbGeAlD
Flutamide—AHR—uterine cervix—ovarian cancer	0.00163	0.046	CbGeAlD
Flutamide—AHR—decidua—ovarian cancer	0.00156	0.0438	CbGeAlD
Flutamide—AHR—endometrium—ovarian cancer	0.00148	0.0416	CbGeAlD
Flutamide—AHR—uterus—ovarian cancer	0.00136	0.0383	CbGeAlD
Flutamide—AHR—female reproductive system—ovarian cancer	0.00122	0.0345	CbGeAlD
Flutamide—AHR—bone marrow—ovarian cancer	0.00115	0.0325	CbGeAlD
Flutamide—AHR—female gonad—ovarian cancer	0.00111	0.0314	CbGeAlD
Flutamide—AHR—vagina—ovarian cancer	0.00111	0.0312	CbGeAlD
Flutamide—AR—myometrium—ovarian cancer	0.00103	0.0292	CbGeAlD
Flutamide—AHR—testis—ovarian cancer	0.000987	0.0278	CbGeAlD
Flutamide—AR—epithelium—ovarian cancer	0.000812	0.0229	CbGeAlD
Flutamide—CYP1B1—decidua—ovarian cancer	0.00081	0.0228	CbGeAlD
Flutamide—AR—uterine cervix—ovarian cancer	0.000805	0.0227	CbGeAlD
Flutamide—AR—decidua—ovarian cancer	0.000767	0.0216	CbGeAlD
Flutamide—AR—endometrium—ovarian cancer	0.000728	0.0205	CbGeAlD
Flutamide—AHR—lymph node—ovarian cancer	0.000715	0.0202	CbGeAlD
Flutamide—CYP1B1—gonad—ovarian cancer	0.000713	0.0201	CbGeAlD
Flutamide—CYP1B1—uterus—ovarian cancer	0.000709	0.02	CbGeAlD
Flutamide—AR—gonad—ovarian cancer	0.000675	0.019	CbGeAlD
Flutamide—AR—uterus—ovarian cancer	0.000671	0.0189	CbGeAlD
Flutamide—CYP1B1—female reproductive system—ovarian cancer	0.000637	0.018	CbGeAlD
Flutamide—CYP1A1—epithelium—ovarian cancer	0.000606	0.0171	CbGeAlD
Flutamide—AR—female reproductive system—ovarian cancer	0.000603	0.017	CbGeAlD
Flutamide—CYP1A1—uterine cervix—ovarian cancer	0.000601	0.0169	CbGeAlD
Flutamide—CYP3A5—uterine cervix—ovarian cancer	0.000588	0.0166	CbGeAlD
Flutamide—CYP1B1—female gonad—ovarian cancer	0.00058	0.0163	CbGeAlD
Flutamide—AR—female gonad—ovarian cancer	0.000549	0.0155	CbGeAlD
Flutamide—AR—vagina—ovarian cancer	0.000546	0.0154	CbGeAlD
Flutamide—CYP1B1—testis—ovarian cancer	0.000514	0.0145	CbGeAlD
Flutamide—CYP2C19—vagina—ovarian cancer	0.000506	0.0142	CbGeAlD
Flutamide—CYP1A1—uterus—ovarian cancer	0.000501	0.0141	CbGeAlD
Flutamide—AR—testis—ovarian cancer	0.000487	0.0137	CbGeAlD
Flutamide—CYP1A1—female reproductive system—ovarian cancer	0.00045	0.0127	CbGeAlD
Flutamide—CYP1A1—female gonad—ovarian cancer	0.00041	0.0115	CbGeAlD
Flutamide—CYP1A1—vagina—ovarian cancer	0.000407	0.0115	CbGeAlD
Flutamide—CYP3A5—female gonad—ovarian cancer	0.000401	0.0113	CbGeAlD
Flutamide—CYP3A5—vagina—ovarian cancer	0.000398	0.0112	CbGeAlD
Flutamide—CYP1B1—lymph node—ovarian cancer	0.000373	0.0105	CbGeAlD
Flutamide—AR—lymph node—ovarian cancer	0.000353	0.00995	CbGeAlD
Flutamide—CYP3A4—female reproductive system—ovarian cancer	0.00033	0.00931	CbGeAlD
Flutamide—Liver injury—Epirubicin—ovarian cancer	0.000311	0.0024	CcSEcCtD
Flutamide—Neoplasm malignant—Epirubicin—ovarian cancer	0.000307	0.00236	CcSEcCtD
Flutamide—Leukopenia—Melphalan—ovarian cancer	0.000305	0.00235	CcSEcCtD
Flutamide—Anorexia—Chlorambucil—ovarian cancer	0.000304	0.00234	CcSEcCtD
Flutamide—Hot flush—Docetaxel—ovarian cancer	0.000301	0.00232	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Paclitaxel—ovarian cancer	0.000299	0.00231	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Paclitaxel—ovarian cancer	0.000299	0.00231	CcSEcCtD
Flutamide—Menopausal symptoms—Docetaxel—ovarian cancer	0.000299	0.0023	CcSEcCtD
Flutamide—Jaundice cholestatic—Epirubicin—ovarian cancer	0.000298	0.0023	CcSEcCtD
Flutamide—Erythema—Vinorelbine—ovarian cancer	0.000298	0.00229	CcSEcCtD
Flutamide—Dermatitis bullous—Docetaxel—ovarian cancer	0.000295	0.00227	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.000294	0.00227	CcSEcCtD
Flutamide—Discomfort—Topotecan—ovarian cancer	0.000293	0.00226	CcSEcCtD
Flutamide—Rectal haemorrhage—Epirubicin—ovarian cancer	0.00029	0.00223	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.000288	0.00222	CcSEcCtD
Flutamide—Liver injury—Doxorubicin—ovarian cancer	0.000288	0.00222	CcSEcCtD
Flutamide—Neoplasm malignant—Doxorubicin—ovarian cancer	0.000284	0.00219	CcSEcCtD
Flutamide—Oedema—Melphalan—ovarian cancer	0.000278	0.00214	CcSEcCtD
Flutamide—Thrombocytopenia—Topotecan—ovarian cancer	0.000278	0.00214	CcSEcCtD
Flutamide—Decreased appetite—Chlorambucil—ovarian cancer	0.000277	0.00214	CcSEcCtD
Flutamide—Ulcer—Epirubicin—ovarian cancer	0.000277	0.00213	CcSEcCtD
Flutamide—Ill-defined disorder—Vinorelbine—ovarian cancer	0.000276	0.00213	CcSEcCtD
Flutamide—Skin disorder—Topotecan—ovarian cancer	0.000276	0.00213	CcSEcCtD
Flutamide—Jaundice cholestatic—Doxorubicin—ovarian cancer	0.000276	0.00212	CcSEcCtD
Flutamide—Anaemia—Vinorelbine—ovarian cancer	0.000275	0.00212	CcSEcCtD
Flutamide—Fatigue—Chlorambucil—ovarian cancer	0.000275	0.00212	CcSEcCtD
Flutamide—Thrombocytopenia—Melphalan—ovarian cancer	0.000272	0.0021	CcSEcCtD
Flutamide—Anorexia—Topotecan—ovarian cancer	0.000271	0.00209	CcSEcCtD
Flutamide—Skin disorder—Melphalan—ovarian cancer	0.00027	0.00208	CcSEcCtD
Flutamide—Malaise—Vinorelbine—ovarian cancer	0.000268	0.00207	CcSEcCtD
Flutamide—Rectal haemorrhage—Doxorubicin—ovarian cancer	0.000268	0.00207	CcSEcCtD
Flutamide—Leukopenia—Vinorelbine—ovarian cancer	0.000266	0.00205	CcSEcCtD
Flutamide—Anorexia—Melphalan—ovarian cancer	0.000265	0.00204	CcSEcCtD
Flutamide—CYP1A1—lymph node—ovarian cancer	0.000263	0.00743	CbGeAlD
Flutamide—Feeling abnormal—Chlorambucil—ovarian cancer	0.000263	0.00203	CcSEcCtD
Flutamide—Photosensitivity reaction—Paclitaxel—ovarian cancer	0.000262	0.00202	CcSEcCtD
Flutamide—Pulmonary embolism—Epirubicin—ovarian cancer	0.000262	0.00202	CcSEcCtD
Flutamide—Hyperglycaemia—Paclitaxel—ovarian cancer	0.000259	0.002	CcSEcCtD
Flutamide—Hypertension—Vinorelbine—ovarian cancer	0.000257	0.00198	CcSEcCtD
Flutamide—Ulcer—Doxorubicin—ovarian cancer	0.000256	0.00197	CcSEcCtD
Flutamide—Cystitis noninfective—Epirubicin—ovarian cancer	0.000256	0.00197	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Docetaxel—ovarian cancer	0.000254	0.00196	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.000254	0.00196	CcSEcCtD
Flutamide—Cystitis—Epirubicin—ovarian cancer	0.000253	0.00195	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000252	0.00194	CcSEcCtD
Flutamide—Discomfort—Vinorelbine—ovarian cancer	0.00025	0.00193	CcSEcCtD
Flutamide—Blood urea increased—Epirubicin—ovarian cancer	0.000247	0.0019	CcSEcCtD
Flutamide—Decreased appetite—Topotecan—ovarian cancer	0.000247	0.0019	CcSEcCtD
Flutamide—Fatigue—Topotecan—ovarian cancer	0.000245	0.00189	CcSEcCtD
Flutamide—Haematuria—Paclitaxel—ovarian cancer	0.000244	0.00188	CcSEcCtD
Flutamide—Constipation—Topotecan—ovarian cancer	0.000243	0.00187	CcSEcCtD
Flutamide—Pulmonary embolism—Doxorubicin—ovarian cancer	0.000242	0.00187	CcSEcCtD
Flutamide—Decreased appetite—Melphalan—ovarian cancer	0.000242	0.00186	CcSEcCtD
Flutamide—Fatigue—Melphalan—ovarian cancer	0.00024	0.00185	CcSEcCtD
Flutamide—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000238	0.00183	CcSEcCtD
Flutamide—Ecchymosis—Epirubicin—ovarian cancer	0.000237	0.00182	CcSEcCtD
Flutamide—Bladder pain—Epirubicin—ovarian cancer	0.000237	0.00182	CcSEcCtD
Flutamide—Neoplasm—Epirubicin—ovarian cancer	0.000237	0.00182	CcSEcCtD
Flutamide—Cystitis noninfective—Doxorubicin—ovarian cancer	0.000237	0.00182	CcSEcCtD
Flutamide—Skin disorder—Vinorelbine—ovarian cancer	0.000236	0.00182	CcSEcCtD
Flutamide—Feeling abnormal—Topotecan—ovarian cancer	0.000234	0.0018	CcSEcCtD
Flutamide—Cystitis—Doxorubicin—ovarian cancer	0.000234	0.0018	CcSEcCtD
Flutamide—Anorexia—Vinorelbine—ovarian cancer	0.000232	0.00178	CcSEcCtD
Flutamide—Asthenia—Chlorambucil—ovarian cancer	0.000229	0.00176	CcSEcCtD
Flutamide—Blood urea increased—Doxorubicin—ovarian cancer	0.000229	0.00176	CcSEcCtD
Flutamide—Oedema peripheral—Paclitaxel—ovarian cancer	0.000227	0.00175	CcSEcCtD
Flutamide—Pruritus—Chlorambucil—ovarian cancer	0.000226	0.00174	CcSEcCtD
Flutamide—Ecchymosis—Doxorubicin—ovarian cancer	0.000219	0.00169	CcSEcCtD
Flutamide—Neoplasm—Doxorubicin—ovarian cancer	0.000219	0.00169	CcSEcCtD
Flutamide—Bladder pain—Doxorubicin—ovarian cancer	0.000219	0.00169	CcSEcCtD
Flutamide—Diabetes mellitus—Epirubicin—ovarian cancer	0.000219	0.00168	CcSEcCtD
Flutamide—Diarrhoea—Chlorambucil—ovarian cancer	0.000218	0.00168	CcSEcCtD
Flutamide—Jaundice—Docetaxel—ovarian cancer	0.000212	0.00163	CcSEcCtD
Flutamide—Decreased appetite—Vinorelbine—ovarian cancer	0.000211	0.00163	CcSEcCtD
Flutamide—Fatigue—Vinorelbine—ovarian cancer	0.000209	0.00161	CcSEcCtD
Flutamide—Constipation—Vinorelbine—ovarian cancer	0.000208	0.0016	CcSEcCtD
Flutamide—Asthenia—Topotecan—ovarian cancer	0.000204	0.00157	CcSEcCtD
Flutamide—Hot flush—Epirubicin—ovarian cancer	0.000203	0.00157	CcSEcCtD
Flutamide—Vomiting—Chlorambucil—ovarian cancer	0.000203	0.00156	CcSEcCtD
Flutamide—Increased appetite—Epirubicin—ovarian cancer	0.000202	0.00156	CcSEcCtD
Flutamide—Diabetes mellitus—Doxorubicin—ovarian cancer	0.000202	0.00156	CcSEcCtD
Flutamide—Menopausal symptoms—Epirubicin—ovarian cancer	0.000201	0.00155	CcSEcCtD
Flutamide—Pruritus—Topotecan—ovarian cancer	0.000201	0.00155	CcSEcCtD
Flutamide—Erythema—Paclitaxel—ovarian cancer	0.0002	0.00154	CcSEcCtD
Flutamide—Feeling abnormal—Vinorelbine—ovarian cancer	0.0002	0.00154	CcSEcCtD
Flutamide—Asthenia—Melphalan—ovarian cancer	0.0002	0.00154	CcSEcCtD
Flutamide—Dermatitis bullous—Epirubicin—ovarian cancer	0.000199	0.00153	CcSEcCtD
Flutamide—Pruritus—Melphalan—ovarian cancer	0.000197	0.00152	CcSEcCtD
Flutamide—Tension—Paclitaxel—ovarian cancer	0.000196	0.00151	CcSEcCtD
Flutamide—Hepatitis—Docetaxel—ovarian cancer	0.000195	0.0015	CcSEcCtD
Flutamide—Nervousness—Paclitaxel—ovarian cancer	0.000194	0.0015	CcSEcCtD
Flutamide—Diarrhoea—Topotecan—ovarian cancer	0.000194	0.0015	CcSEcCtD
Flutamide—Oedema peripheral—Docetaxel—ovarian cancer	0.000192	0.00148	CcSEcCtD
Flutamide—Diarrhoea—Melphalan—ovarian cancer	0.00019	0.00147	CcSEcCtD
Flutamide—Nausea—Chlorambucil—ovarian cancer	0.000189	0.00146	CcSEcCtD
Flutamide—Hot flush—Doxorubicin—ovarian cancer	0.000188	0.00145	CcSEcCtD
Flutamide—Dizziness—Topotecan—ovarian cancer	0.000188	0.00145	CcSEcCtD
Flutamide—Increased appetite—Doxorubicin—ovarian cancer	0.000187	0.00144	CcSEcCtD
Flutamide—Menopausal symptoms—Doxorubicin—ovarian cancer	0.000186	0.00144	CcSEcCtD
Flutamide—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000186	0.00143	CcSEcCtD
Flutamide—Anaemia—Paclitaxel—ovarian cancer	0.000185	0.00143	CcSEcCtD
Flutamide—Dermatitis bullous—Doxorubicin—ovarian cancer	0.000184	0.00142	CcSEcCtD
Flutamide—Vomiting—Topotecan—ovarian cancer	0.000181	0.00139	CcSEcCtD
Flutamide—Malaise—Paclitaxel—ovarian cancer	0.000181	0.00139	CcSEcCtD
Flutamide—Leukopenia—Paclitaxel—ovarian cancer	0.000179	0.00138	CcSEcCtD
Flutamide—Rash—Topotecan—ovarian cancer	0.000179	0.00138	CcSEcCtD
Flutamide—Dermatitis—Topotecan—ovarian cancer	0.000179	0.00138	CcSEcCtD
Flutamide—Headache—Topotecan—ovarian cancer	0.000178	0.00137	CcSEcCtD
Flutamide—Vomiting—Melphalan—ovarian cancer	0.000177	0.00136	CcSEcCtD
Flutamide—Rash—Melphalan—ovarian cancer	0.000175	0.00135	CcSEcCtD
Flutamide—Dermatitis—Melphalan—ovarian cancer	0.000175	0.00135	CcSEcCtD
Flutamide—Asthenia—Vinorelbine—ovarian cancer	0.000174	0.00134	CcSEcCtD
Flutamide—Hypertension—Paclitaxel—ovarian cancer	0.000173	0.00133	CcSEcCtD
Flutamide—Pruritus—Vinorelbine—ovarian cancer	0.000172	0.00132	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000171	0.00132	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000171	0.00132	CcSEcCtD
Flutamide—Anxiety—Paclitaxel—ovarian cancer	0.00017	0.00131	CcSEcCtD
Flutamide—Erythema—Docetaxel—ovarian cancer	0.00017	0.00131	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000169	0.0013	CcSEcCtD
Flutamide—Nausea—Topotecan—ovarian cancer	0.000169	0.0013	CcSEcCtD
Flutamide—Discomfort—Paclitaxel—ovarian cancer	0.000168	0.0013	CcSEcCtD
Flutamide—Diarrhoea—Vinorelbine—ovarian cancer	0.000166	0.00128	CcSEcCtD
Flutamide—Nausea—Melphalan—ovarian cancer	0.000165	0.00127	CcSEcCtD
Flutamide—Confusional state—Paclitaxel—ovarian cancer	0.000165	0.00127	CcSEcCtD
Flutamide—Oedema—Paclitaxel—ovarian cancer	0.000163	0.00126	CcSEcCtD
Flutamide—Dizziness—Vinorelbine—ovarian cancer	0.000161	0.00124	CcSEcCtD
Flutamide—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00016	0.00123	CcSEcCtD
Flutamide—Skin disorder—Paclitaxel—ovarian cancer	0.000159	0.00122	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000158	0.00122	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000158	0.00122	CcSEcCtD
Flutamide—Anaemia—Docetaxel—ovarian cancer	0.000157	0.00121	CcSEcCtD
Flutamide—Anorexia—Paclitaxel—ovarian cancer	0.000156	0.0012	CcSEcCtD
Flutamide—Vomiting—Vinorelbine—ovarian cancer	0.000154	0.00119	CcSEcCtD
Flutamide—Rash—Vinorelbine—ovarian cancer	0.000153	0.00118	CcSEcCtD
Flutamide—Dermatitis—Vinorelbine—ovarian cancer	0.000153	0.00118	CcSEcCtD
Flutamide—Headache—Vinorelbine—ovarian cancer	0.000152	0.00117	CcSEcCtD
Flutamide—Leukopenia—Docetaxel—ovarian cancer	0.000152	0.00117	CcSEcCtD
Flutamide—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00015	0.00116	CcSEcCtD
Flutamide—Hyperglycaemia—Epirubicin—ovarian cancer	0.000148	0.00114	CcSEcCtD
Flutamide—Insomnia—Paclitaxel—ovarian cancer	0.000148	0.00114	CcSEcCtD
Flutamide—Hypertension—Docetaxel—ovarian cancer	0.000147	0.00113	CcSEcCtD
Flutamide—Drowsiness—Epirubicin—ovarian cancer	0.000146	0.00113	CcSEcCtD
Flutamide—Somnolence—Paclitaxel—ovarian cancer	0.000145	0.00112	CcSEcCtD
Flutamide—Nausea—Vinorelbine—ovarian cancer	0.000144	0.00111	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000143	0.00111	CcSEcCtD
Flutamide—Jaundice—Epirubicin—ovarian cancer	0.000143	0.0011	CcSEcCtD
Flutamide—Decreased appetite—Paclitaxel—ovarian cancer	0.000142	0.00109	CcSEcCtD
Flutamide—Fatigue—Paclitaxel—ovarian cancer	0.000141	0.00109	CcSEcCtD
Flutamide—Constipation—Paclitaxel—ovarian cancer	0.00014	0.00108	CcSEcCtD
Flutamide—Haematuria—Epirubicin—ovarian cancer	0.00014	0.00108	CcSEcCtD
Flutamide—Confusional state—Docetaxel—ovarian cancer	0.00014	0.00108	CcSEcCtD
Flutamide—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000139	0.00107	CcSEcCtD
Flutamide—Oedema—Docetaxel—ovarian cancer	0.000139	0.00107	CcSEcCtD
Flutamide—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000137	0.00106	CcSEcCtD
Flutamide—Thrombocytopenia—Docetaxel—ovarian cancer	0.000136	0.00104	CcSEcCtD
Flutamide—Drowsiness—Doxorubicin—ovarian cancer	0.000136	0.00104	CcSEcCtD
Flutamide—Feeling abnormal—Paclitaxel—ovarian cancer	0.000135	0.00104	CcSEcCtD
Flutamide—Skin disorder—Docetaxel—ovarian cancer	0.000135	0.00104	CcSEcCtD
Flutamide—Jaundice—Doxorubicin—ovarian cancer	0.000132	0.00102	CcSEcCtD
Flutamide—Anorexia—Docetaxel—ovarian cancer	0.000132	0.00102	CcSEcCtD
Flutamide—Hepatitis—Epirubicin—ovarian cancer	0.000132	0.00101	CcSEcCtD
Flutamide—Oedema peripheral—Epirubicin—ovarian cancer	0.00013	0.000998	CcSEcCtD
Flutamide—Haematuria—Doxorubicin—ovarian cancer	0.000129	0.000996	CcSEcCtD
Flutamide—Insomnia—Docetaxel—ovarian cancer	0.000125	0.000965	CcSEcCtD
Flutamide—Somnolence—Docetaxel—ovarian cancer	0.000123	0.000949	CcSEcCtD
Flutamide—Hepatitis—Doxorubicin—ovarian cancer	0.000122	0.000937	CcSEcCtD
Flutamide—Decreased appetite—Docetaxel—ovarian cancer	0.00012	0.000928	CcSEcCtD
Flutamide—Oedema peripheral—Doxorubicin—ovarian cancer	0.00012	0.000923	CcSEcCtD
Flutamide—Fatigue—Docetaxel—ovarian cancer	0.000119	0.00092	CcSEcCtD
Flutamide—Constipation—Docetaxel—ovarian cancer	0.000118	0.000913	CcSEcCtD
Flutamide—Asthenia—Paclitaxel—ovarian cancer	0.000117	0.000903	CcSEcCtD
Flutamide—Pruritus—Paclitaxel—ovarian cancer	0.000116	0.000891	CcSEcCtD
Flutamide—Erythema—Epirubicin—ovarian cancer	0.000114	0.000882	CcSEcCtD
Flutamide—Feeling abnormal—Docetaxel—ovarian cancer	0.000114	0.000879	CcSEcCtD
Flutamide—Tension—Epirubicin—ovarian cancer	0.000112	0.000865	CcSEcCtD
Flutamide—Diarrhoea—Paclitaxel—ovarian cancer	0.000112	0.000861	CcSEcCtD
Flutamide—Nervousness—Epirubicin—ovarian cancer	0.000111	0.000857	CcSEcCtD
Flutamide—Dizziness—Paclitaxel—ovarian cancer	0.000108	0.000833	CcSEcCtD
Flutamide—Ill-defined disorder—Epirubicin—ovarian cancer	0.000106	0.000818	CcSEcCtD
Flutamide—Erythema—Doxorubicin—ovarian cancer	0.000106	0.000816	CcSEcCtD
Flutamide—Anaemia—Epirubicin—ovarian cancer	0.000106	0.000815	CcSEcCtD
Flutamide—Tension—Doxorubicin—ovarian cancer	0.000104	0.000801	CcSEcCtD
Flutamide—Vomiting—Paclitaxel—ovarian cancer	0.000104	0.0008	CcSEcCtD
Flutamide—Malaise—Epirubicin—ovarian cancer	0.000103	0.000795	CcSEcCtD
Flutamide—Rash—Paclitaxel—ovarian cancer	0.000103	0.000794	CcSEcCtD
Flutamide—Dermatitis—Paclitaxel—ovarian cancer	0.000103	0.000793	CcSEcCtD
Flutamide—Nervousness—Doxorubicin—ovarian cancer	0.000103	0.000793	CcSEcCtD
Flutamide—Leukopenia—Epirubicin—ovarian cancer	0.000102	0.000789	CcSEcCtD
Flutamide—Headache—Paclitaxel—ovarian cancer	0.000102	0.000789	CcSEcCtD
Flutamide—Asthenia—Docetaxel—ovarian cancer	9.94e-05	0.000766	CcSEcCtD
Flutamide—Hypertension—Epirubicin—ovarian cancer	9.88e-05	0.000761	CcSEcCtD
Flutamide—Ill-defined disorder—Doxorubicin—ovarian cancer	9.83e-05	0.000757	CcSEcCtD
Flutamide—Pruritus—Docetaxel—ovarian cancer	9.8e-05	0.000755	CcSEcCtD
Flutamide—Anaemia—Doxorubicin—ovarian cancer	9.79e-05	0.000754	CcSEcCtD
Flutamide—Anxiety—Epirubicin—ovarian cancer	9.71e-05	0.000748	CcSEcCtD
Flutamide—Nausea—Paclitaxel—ovarian cancer	9.71e-05	0.000748	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	9.68e-05	0.000746	CcSEcCtD
Flutamide—Discomfort—Epirubicin—ovarian cancer	9.63e-05	0.000742	CcSEcCtD
Flutamide—Malaise—Doxorubicin—ovarian cancer	9.55e-05	0.000736	CcSEcCtD
Flutamide—Leukopenia—Doxorubicin—ovarian cancer	9.48e-05	0.00073	CcSEcCtD
Flutamide—Diarrhoea—Docetaxel—ovarian cancer	9.48e-05	0.00073	CcSEcCtD
Flutamide—Confusional state—Epirubicin—ovarian cancer	9.42e-05	0.000726	CcSEcCtD
Flutamide—Oedema—Epirubicin—ovarian cancer	9.34e-05	0.00072	CcSEcCtD
Flutamide—Dizziness—Docetaxel—ovarian cancer	9.16e-05	0.000706	CcSEcCtD
Flutamide—Thrombocytopenia—Epirubicin—ovarian cancer	9.15e-05	0.000705	CcSEcCtD
Flutamide—Hypertension—Doxorubicin—ovarian cancer	9.14e-05	0.000705	CcSEcCtD
Flutamide—Skin disorder—Epirubicin—ovarian cancer	9.07e-05	0.000699	CcSEcCtD
Flutamide—Anxiety—Doxorubicin—ovarian cancer	8.99e-05	0.000692	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	8.96e-05	0.00069	CcSEcCtD
Flutamide—Discomfort—Doxorubicin—ovarian cancer	8.91e-05	0.000686	CcSEcCtD
Flutamide—Anorexia—Epirubicin—ovarian cancer	8.91e-05	0.000686	CcSEcCtD
Flutamide—Vomiting—Docetaxel—ovarian cancer	8.81e-05	0.000678	CcSEcCtD
Flutamide—Rash—Docetaxel—ovarian cancer	8.73e-05	0.000673	CcSEcCtD
Flutamide—Dermatitis—Docetaxel—ovarian cancer	8.73e-05	0.000672	CcSEcCtD
Flutamide—Confusional state—Doxorubicin—ovarian cancer	8.72e-05	0.000672	CcSEcCtD
Flutamide—Headache—Docetaxel—ovarian cancer	8.68e-05	0.000669	CcSEcCtD
Flutamide—Oedema—Doxorubicin—ovarian cancer	8.64e-05	0.000666	CcSEcCtD
Flutamide—Thrombocytopenia—Doxorubicin—ovarian cancer	8.46e-05	0.000652	CcSEcCtD
Flutamide—Insomnia—Epirubicin—ovarian cancer	8.45e-05	0.000651	CcSEcCtD
Flutamide—Skin disorder—Doxorubicin—ovarian cancer	8.4e-05	0.000647	CcSEcCtD
Flutamide—Somnolence—Epirubicin—ovarian cancer	8.31e-05	0.00064	CcSEcCtD
Flutamide—Anorexia—Doxorubicin—ovarian cancer	8.24e-05	0.000635	CcSEcCtD
Flutamide—Nausea—Docetaxel—ovarian cancer	8.23e-05	0.000634	CcSEcCtD
Flutamide—Decreased appetite—Epirubicin—ovarian cancer	8.12e-05	0.000626	CcSEcCtD
Flutamide—Fatigue—Epirubicin—ovarian cancer	8.05e-05	0.000621	CcSEcCtD
Flutamide—Constipation—Epirubicin—ovarian cancer	7.99e-05	0.000616	CcSEcCtD
Flutamide—Insomnia—Doxorubicin—ovarian cancer	7.82e-05	0.000602	CcSEcCtD
Flutamide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—ovarian cancer	7.77e-05	0.00149	CbGpPWpGaD
Flutamide—Feeling abnormal—Epirubicin—ovarian cancer	7.7e-05	0.000593	CcSEcCtD
Flutamide—Somnolence—Doxorubicin—ovarian cancer	7.68e-05	0.000592	CcSEcCtD
Flutamide—Decreased appetite—Doxorubicin—ovarian cancer	7.51e-05	0.000579	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—IL6—ovarian cancer	7.51e-05	0.00144	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	7.49e-05	0.00144	CbGpPWpGaD
Flutamide—Fatigue—Doxorubicin—ovarian cancer	7.45e-05	0.000574	CcSEcCtD
Flutamide—Constipation—Doxorubicin—ovarian cancer	7.39e-05	0.00057	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	7.34e-05	0.00141	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	7.34e-05	0.00141	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—YAP1—ovarian cancer	7.21e-05	0.00139	CbGpPWpGaD
Flutamide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	7.18e-05	0.00138	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	7.18e-05	0.00138	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	7.16e-05	0.00138	CbGpPWpGaD
Flutamide—Feeling abnormal—Doxorubicin—ovarian cancer	7.12e-05	0.000549	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—CDH1—ovarian cancer	7.11e-05	0.00137	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—ovarian cancer	7.06e-05	0.00136	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—ovarian cancer	7e-05	0.00134	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—STAT3—ovarian cancer	6.98e-05	0.00134	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	6.88e-05	0.00132	CbGpPWpGaD
Flutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	6.84e-05	0.00131	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	6.77e-05	0.0013	CbGpPWpGaD
Flutamide—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	6.75e-05	0.0013	CbGpPWpGaD
Flutamide—AR—Gene Expression—TTF1—ovarian cancer	6.71e-05	0.00129	CbGpPWpGaD
Flutamide—Asthenia—Epirubicin—ovarian cancer	6.7e-05	0.000516	CcSEcCtD
Flutamide—Pruritus—Epirubicin—ovarian cancer	6.61e-05	0.000509	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	6.4e-05	0.00123	CbGpPWpGaD
Flutamide—Diarrhoea—Epirubicin—ovarian cancer	6.39e-05	0.000492	CcSEcCtD
Flutamide—AR—Androgen receptor signaling pathway—EGFR—ovarian cancer	6.35e-05	0.00122	CbGpPWpGaD
Flutamide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—FASN—ovarian cancer	6.33e-05	0.00122	CbGpPWpGaD
Flutamide—CYP3A5—Biological oxidations—CYP1B1—ovarian cancer	6.33e-05	0.00122	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—PGR—ovarian cancer	6.3e-05	0.00121	CbGpPWpGaD
Flutamide—CYP3A5—Metapathway biotransformation—CYP1B1—ovarian cancer	6.25e-05	0.0012	CbGpPWpGaD
Flutamide—Asthenia—Doxorubicin—ovarian cancer	6.2e-05	0.000478	CcSEcCtD
Flutamide—Dizziness—Epirubicin—ovarian cancer	6.18e-05	0.000476	CcSEcCtD
Flutamide—Pruritus—Doxorubicin—ovarian cancer	6.12e-05	0.000471	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	6.1e-05	0.00117	CbGpPWpGaD
Flutamide—AR—Gene Expression—NR5A1—ovarian cancer	6.09e-05	0.00117	CbGpPWpGaD
Flutamide—AR—Coregulation of Androgen receptor activity—AKT1—ovarian cancer	6.09e-05	0.00117	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	6.03e-05	0.00116	CbGpPWpGaD
Flutamide—CYP1A1—Biological oxidations—CYP1B1—ovarian cancer	5.98e-05	0.00115	CbGpPWpGaD
Flutamide—Vomiting—Epirubicin—ovarian cancer	5.94e-05	0.000458	CcSEcCtD
Flutamide—CYP1B1—Metabolism—NME2—ovarian cancer	5.92e-05	0.00114	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	5.92e-05	0.00114	CbGpPWpGaD
Flutamide—Diarrhoea—Doxorubicin—ovarian cancer	5.91e-05	0.000456	CcSEcCtD
Flutamide—CYP1A1—Metapathway biotransformation—CYP1B1—ovarian cancer	5.9e-05	0.00113	CbGpPWpGaD
Flutamide—Rash—Epirubicin—ovarian cancer	5.89e-05	0.000454	CcSEcCtD
Flutamide—Dermatitis—Epirubicin—ovarian cancer	5.89e-05	0.000453	CcSEcCtD
Flutamide—AR—Generic Transcription Pathway—PARP1—ovarian cancer	5.86e-05	0.00113	CbGpPWpGaD
Flutamide—Headache—Epirubicin—ovarian cancer	5.85e-05	0.000451	CcSEcCtD
Flutamide—Dizziness—Doxorubicin—ovarian cancer	5.72e-05	0.00044	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	5.61e-05	0.00108	CbGpPWpGaD
Flutamide—Nausea—Epirubicin—ovarian cancer	5.55e-05	0.000428	CcSEcCtD
Flutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	5.54e-05	0.00107	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	5.54e-05	0.00107	CbGpPWpGaD
Flutamide—Vomiting—Doxorubicin—ovarian cancer	5.5e-05	0.000423	CcSEcCtD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	5.49e-05	0.00106	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	5.49e-05	0.00106	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	5.49e-05	0.00106	CbGpPWpGaD
Flutamide—Rash—Doxorubicin—ovarian cancer	5.45e-05	0.00042	CcSEcCtD
Flutamide—Dermatitis—Doxorubicin—ovarian cancer	5.45e-05	0.00042	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	5.44e-05	0.00105	CbGpPWpGaD
Flutamide—Headache—Doxorubicin—ovarian cancer	5.42e-05	0.000417	CcSEcCtD
Flutamide—AR—SIDS Susceptibility Pathways—CASP3—ovarian cancer	5.3e-05	0.00102	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	5.3e-05	0.00102	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	5.25e-05	0.00101	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	5.19e-05	0.000997	CbGpPWpGaD
Flutamide—Nausea—Doxorubicin—ovarian cancer	5.13e-05	0.000396	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	5.11e-05	0.000983	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	5.11e-05	0.000983	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	5.02e-05	0.000966	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	4.97e-05	0.000955	CbGpPWpGaD
Flutamide—CYP2C19—Biological oxidations—CYP1B1—ovarian cancer	4.9e-05	0.000941	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	4.85e-05	0.000932	CbGpPWpGaD
Flutamide—CYP2C19—Metapathway biotransformation—CYP1B1—ovarian cancer	4.83e-05	0.000928	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	4.68e-05	0.000899	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	4.68e-05	0.000899	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	4.62e-05	0.000888	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	4.61e-05	0.000887	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	4.6e-05	0.000885	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	4.58e-05	0.00088	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	4.51e-05	0.000867	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	4.5e-05	0.000865	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—AKT1—ovarian cancer	4.5e-05	0.000865	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	4.41e-05	0.000847	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	4.39e-05	0.000844	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	4.35e-05	0.000836	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—MYC—ovarian cancer	4.25e-05	0.000817	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	4.24e-05	0.000814	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	4.16e-05	0.000799	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	4.16e-05	0.000799	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.1e-05	0.000787	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	3.93e-05	0.000755	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	3.89e-05	0.000748	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—NME2—ovarian cancer	3.86e-05	0.000742	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	3.84e-05	0.000738	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	3.83e-05	0.000736	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—CYTB—ovarian cancer	3.82e-05	0.000734	CbGpPWpGaD
Flutamide—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	3.81e-05	0.000733	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	3.78e-05	0.000726	CbGpPWpGaD
Flutamide—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	3.76e-05	0.000723	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—NME2—ovarian cancer	3.65e-05	0.000701	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	3.62e-05	0.000696	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	3.58e-05	0.000688	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	3.52e-05	0.000677	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	3.5e-05	0.000673	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	3.5e-05	0.000673	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	3.5e-05	0.000673	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—TP53—ovarian cancer	3.49e-05	0.000671	CbGpPWpGaD
Flutamide—AR—Gene Expression—YAP1—ovarian cancer	3.47e-05	0.000668	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	3.45e-05	0.000662	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	3.44e-05	0.000662	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—ESR1—ovarian cancer	3.36e-05	0.000646	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PPP1CC—ovarian cancer	3.34e-05	0.000641	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—BRIP1—ovarian cancer	3.34e-05	0.000641	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	3.31e-05	0.000636	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	3.25e-05	0.000625	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—IL6—ovarian cancer	3.11e-05	0.000598	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.09e-05	0.000595	CbGpPWpGaD
Flutamide—AR—Gene Expression—PGR—ovarian cancer	3.03e-05	0.000583	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.99e-05	0.000575	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—NME2—ovarian cancer	2.99e-05	0.000574	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	2.95e-05	0.000566	CbGpPWpGaD
Flutamide—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	2.94e-05	0.000566	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	2.94e-05	0.000565	CbGpPWpGaD
Flutamide—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	2.9e-05	0.000558	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.89e-05	0.000556	CbGpPWpGaD
Flutamide—AR—Gene Expression—PARP1—ovarian cancer	2.82e-05	0.000542	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	2.81e-05	0.00054	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.53e-05	0.000487	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.52e-05	0.000485	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CYTB—ovarian cancer	2.49e-05	0.000478	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.44e-05	0.000469	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.43e-05	0.000467	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CYTB—ovarian cancer	2.35e-05	0.000452	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—NME2—ovarian cancer	2.33e-05	0.000447	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.3e-05	0.000442	CbGpPWpGaD
Flutamide—AR—Gene Expression—PPP2R1A—ovarian cancer	2.29e-05	0.00044	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—YAP1—ovarian cancer	2.24e-05	0.00043	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.21e-05	0.000426	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PPP1CC—ovarian cancer	2.17e-05	0.000418	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—BRIP1—ovarian cancer	2.17e-05	0.000418	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.06e-05	0.000397	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—BRIP1—ovarian cancer	2.05e-05	0.000395	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PPP1CC—ovarian cancer	2.05e-05	0.000395	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.97e-05	0.000379	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.95e-05	0.000374	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CYTB—ovarian cancer	1.92e-05	0.00037	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.88e-05	0.000361	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—FASN—ovarian cancer	1.82e-05	0.000351	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—NME2—ovarian cancer	1.8e-05	0.000345	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—SLC5A5—ovarian cancer	1.79e-05	0.000345	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—MYC—ovarian cancer	1.75e-05	0.000336	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—SLC2A1—ovarian cancer	1.73e-05	0.000333	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.7e-05	0.000326	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PPP1CC—ovarian cancer	1.68e-05	0.000323	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—BRIP1—ovarian cancer	1.68e-05	0.000323	CbGpPWpGaD
Flutamide—AR—Gene Expression—ESR1—ovarian cancer	1.62e-05	0.000311	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.61e-05	0.000309	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CYTB—ovarian cancer	1.5e-05	0.000288	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.5e-05	0.000288	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PPP2R1A—ovarian cancer	1.47e-05	0.000283	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.47e-05	0.000282	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.46e-05	0.000282	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—YAP1—ovarian cancer	1.46e-05	0.00028	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—YAP1—ovarian cancer	1.38e-05	0.000265	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—ABCB1—ovarian cancer	1.37e-05	0.000263	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.36e-05	0.000262	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—TYMS—ovarian cancer	1.34e-05	0.000258	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PPP1CC—ovarian cancer	1.31e-05	0.000252	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—BRIP1—ovarian cancer	1.31e-05	0.000252	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.23e-05	0.000235	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.2e-05	0.00023	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—FASN—ovarian cancer	1.19e-05	0.000229	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—SLC5A5—ovarian cancer	1.17e-05	0.000225	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CYTB—ovarian cancer	1.16e-05	0.000222	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—SLC2A1—ovarian cancer	1.13e-05	0.000217	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—YAP1—ovarian cancer	1.13e-05	0.000217	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—FASN—ovarian cancer	1.12e-05	0.000216	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.12e-05	0.000214	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—SLC5A5—ovarian cancer	1.11e-05	0.000212	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CYP1B1—ovarian cancer	1.08e-05	0.000208	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—CAV1—ovarian cancer	1.08e-05	0.000208	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—SLC2A1—ovarian cancer	1.07e-05	0.000205	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.05e-05	0.000201	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.03e-05	0.000199	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CYP1B1—ovarian cancer	1.02e-05	0.000197	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.01e-05	0.000194	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.01e-05	0.000194	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PIK3CG—ovarian cancer	9.86e-06	0.00019	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.81e-06	0.000189	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	9.6e-06	0.000185	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	9.55e-06	0.000183	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—FASN—ovarian cancer	9.19e-06	0.000177	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	9.07e-06	0.000174	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—SLC5A5—ovarian cancer	9.04e-06	0.000174	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.03e-06	0.000174	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—ABCB1—ovarian cancer	8.92e-06	0.000171	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—YAP1—ovarian cancer	8.79e-06	0.000169	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—TYMS—ovarian cancer	8.76e-06	0.000168	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—SLC2A1—ovarian cancer	8.73e-06	0.000168	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.7e-06	0.000167	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PIK3CD—ovarian cancer	8.67e-06	0.000167	CbGpPWpGaD
Flutamide—AR—Gene Expression—MAPK3—ovarian cancer	8.66e-06	0.000166	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.55e-06	0.000164	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—ABCB1—ovarian cancer	8.43e-06	0.000162	CbGpPWpGaD
Flutamide—AR—Gene Expression—MYC—ovarian cancer	8.42e-06	0.000162	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CYP1B1—ovarian cancer	8.37e-06	0.000161	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—TYMS—ovarian cancer	8.28e-06	0.000159	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.64e-06	0.000147	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PIK3CB—ovarian cancer	7.56e-06	0.000145	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	7.43e-06	0.000143	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.39e-06	0.000142	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—FASN—ovarian cancer	7.16e-06	0.000138	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CAV1—ovarian cancer	7.06e-06	0.000136	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—SLC5A5—ovarian cancer	7.05e-06	0.000135	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—ABCB1—ovarian cancer	6.89e-06	0.000133	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—SLC2A1—ovarian cancer	6.8e-06	0.000131	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—YAP1—ovarian cancer	6.78e-06	0.00013	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—TYMS—ovarian cancer	6.77e-06	0.00013	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CAV1—ovarian cancer	6.67e-06	0.000128	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.66e-06	0.000128	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PTEN—ovarian cancer	6.53e-06	0.000126	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CYP1B1—ovarian cancer	6.52e-06	0.000125	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PIK3CG—ovarian cancer	6.43e-06	0.000124	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.37e-06	0.000122	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PIK3CG—ovarian cancer	6.07e-06	0.000117	CbGpPWpGaD
Flutamide—AR—Gene Expression—AKT1—ovarian cancer	5.84e-06	0.000112	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	5.79e-06	0.000111	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.76e-06	0.000111	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PIK3CD—ovarian cancer	5.65e-06	0.000109	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—FASN—ovarian cancer	5.53e-06	0.000106	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CAV1—ovarian cancer	5.46e-06	0.000105	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—SLC5A5—ovarian cancer	5.44e-06	0.000105	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—ABCB1—ovarian cancer	5.37e-06	0.000103	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PIK3CD—ovarian cancer	5.34e-06	0.000103	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—TYMS—ovarian cancer	5.28e-06	0.000101	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—SLC2A1—ovarian cancer	5.25e-06	0.000101	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.21e-06	0.0001	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CYP1B1—ovarian cancer	5.03e-06	9.68e-05	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PIK3CG—ovarian cancer	4.97e-06	9.55e-05	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PIK3CB—ovarian cancer	4.93e-06	9.47e-05	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PIK3CB—ovarian cancer	4.65e-06	8.94e-05	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PIK3CA—ovarian cancer	4.61e-06	8.85e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.47e-06	8.58e-05	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PIK3CD—ovarian cancer	4.37e-06	8.4e-05	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PTEN—ovarian cancer	4.26e-06	8.18e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CAV1—ovarian cancer	4.25e-06	8.17e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.15e-06	7.97e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—TYMS—ovarian cancer	4.07e-06	7.83e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.06e-06	7.81e-05	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PTEN—ovarian cancer	4.02e-06	7.73e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PIK3CG—ovarian cancer	3.87e-06	7.44e-05	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PIK3CB—ovarian cancer	3.81e-06	7.32e-05	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—AKT1—ovarian cancer	3.76e-06	7.23e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PIK3CD—ovarian cancer	3.4e-06	6.54e-05	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PTEN—ovarian cancer	3.29e-06	6.33e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CAV1—ovarian cancer	3.28e-06	6.31e-05	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PIK3CA—ovarian cancer	3e-06	5.77e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.99e-06	5.74e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PIK3CB—ovarian cancer	2.97e-06	5.7e-05	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PIK3CA—ovarian cancer	2.84e-06	5.45e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.63e-06	5.05e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PTEN—ovarian cancer	2.56e-06	4.93e-05	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—AKT1—ovarian cancer	2.45e-06	4.71e-05	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PIK3CA—ovarian cancer	2.32e-06	4.46e-05	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—AKT1—ovarian cancer	2.32e-06	4.45e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.29e-06	4.4e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PTEN—ovarian cancer	1.98e-06	3.8e-05	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—AKT1—ovarian cancer	1.9e-06	3.65e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.81e-06	3.48e-05	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—AKT1—ovarian cancer	1.48e-06	2.84e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.4e-06	2.68e-05	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—AKT1—ovarian cancer	1.14e-06	2.19e-05	CbGpPWpGaD
